This site is intended for U.S. Healthcare Professionals only.

  • US Full Prescribing Information |
  • Medication Guide |
  • Indication

    Indication

    SOTYKTU is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

    Limitations of Use: SOTYKTU is not recommended for use in combination with other potent immunosuppressants.

SOTYKTU™ (deucravacitinib) Logo SOTYKTU™ (deucravacitinib) Logo

Study Designs

Efficacy

Safety

MOA

Dosing

Resources

MENU

CLOSE

Study Designs

Efficacy

Safety

MOA

Dosing

Resources

BMS Connect

Request a Rep

Visit Patient Site

This website is best viewed
using the horizontal display
on your tablet device.

This website is best viewed
using the vertical display
on your mobile device.

WEEK 16 SAFETY PROFILEWEEKS 0-52LTE SAFETY

WEEK 16 SAFETY PROFILE

WEEKS 0-52

LTE SAFETY

Safety Profile1

Week 16 Safety Profile1

ADVERSE REACTIONS THAT OCCURRED IN ≥1% OF PATIENTS TREATED WITH SOTYKTU AND MORE FREQUENTLY THAN PLACEBO THROUGH WEEK 16 FROM PSO-1 AND PSO-21

Adverse reactions through week 16 Adverse reactions through week 16

AR=adverse reaction;
CPK=creatine phosphokinase.

*Includes upper respiratory tract infection (viral, bacterial, and unspecified), nasopharyngitis, pharyngitis (including viral, streptococcal, and unspecified), sinusitis (includes acute, viral, bacterial), rhinitis, rhinotracheitis, tracheitis, laryngitis, and tonsillitis (including bacterial, streptococcal).1

†Includes oral herpes, genital herpes, herpes simplex, and herpes virus infection.1

‡Includes mouth ulceration, aphthous ulcer, tongue ulceration, and stomatitis.1

§Includes acne, acne cystic, and dermatitis acneiform.1

  • Adverse reactions that occurred in <1% of patients in the SOTYKTU group were herpes zoster1
  • Infections: In the first 16 weeks, infections occurred in 29% of the SOTYKTU group (116 events per 100 PY) compared to 22% of the placebo group (83.7 events per 100 PY). The majority of infections were non serious and mild to moderate in severity and did not lead to discontinuation of SOTYKTU. The incidence of serious infections were reported in 5 patients (2.0 per 100 PY) treated with SOTYKTU, and 2 patients (1.6 per 100 PY) treated with placebo.

PY=patient year.

Week 16 Safety Profile (≥5%)2

AEs OCCURRING IN ≥5% OF PATIENTS IN ANY ACTIVE TREATMENT GROUP WEEKS 0-16 FROM POOLED CLINICAL TRIALS (PSO-1 AND PSO-2)2

Safety profile through week 16 Safety profile through week 16

AE=adverse event

*Includes 2 patients in SOTYKTU arm that were excluded from primary and secondary endpoint analyses.1

Discontinuation rates due to all AEs at Week 16 Discontinuation rates due to all AEs at Week 16
  • Studies were not designed to compare the safety of apremilast to SOTYKTU. Some of the observed safety rates for apremilast may differ from those previously reported. Please refer to the apremilast Full Prescribing Information

SAFETY PROFILE THROUGH
WEEK 521,2

Adverse events for SOTYKTU, apremilast, and placebo2

PSO-1 AND PSO-2 POOLED SAFETY, WEEKS 0-522*

POETYK INTEGRATED SAFETY (PSO-1 AND PSO-2), WEEK 0-522*
POETYK INTEGRATED SAFETY (PSO-1 AND PSO-2), WEEK 0-522*

*Includes AEs between first dose and 30 days following last dose or rollover to long-term extension study.2

†Includes 2 patients in SOTYKTU arm that were excluded from primary and secondary endpoint analyses.1

AE=adverse event; AR=adverse reaction; EAIR=exposure-adjusted incidence rate; PY=patient years.

  • Studies were not designed to compare the safety of apremilast to SOTYKTU. Some of the observed safety rates for apremilast may differ from those previously reported. Please refer to the apremilast Full Prescribing Information
  • 1,681 patients were randomized to receive SOTYKTU 6 mg (840 patients), placebo (419 patients), or apremilast 30 mg twice daily (422 patients). All patients randomized to placebo switched to SOTYKTU at Week 16. All other patients remained in their original treatment group until Week 24, at which point patients could have continued on the same treatment or been switched to SOTYKTU or placebo1
  • The most common serious infections reported through Week 52 were pneumonia and COVID-191
  • Malignancies (excluding non-melanoma skin cancer) through Week 52 (total exposure of 986 PY with SOTYKTU) were reported in 3 patients treated with SOTYKTU (0.3/100 PY)1
  • During clinical trials, including an open-label extension trial, 3 SOTYKTU patients (0.1/100 PY) developed lymphoma1
  • Two deaths occurred in the SOTYKTU group while one death occurred in each apremilast and placebo group2
  • One death occurred during Weeks 0-16 in a patient who discontinued SOTYKTU after 4 days of treatment due to prohibited medication (leflunomide) and died 9 days later due to sepsis and heart failure. One additional death occurred during Weeks 16-52 due to hepatocellular carcinoma in a patient with a history of HCV infection and liver cirrhosis
  • The EAIR of adverse reactions in subjects treated with SOTYKTU from Week 0 through Week 52 without switching treatment did not increase compared to the rate observed during the first 16 weeks of treatment1

HCV=hepatitis C virus

SAFETY PROFILE THROUGH
2 YEARS3

Demonstrated safety profile through 2 years in clinical trials3

ADVERSE EVENTS OF SPECIAL INTEREST: POETYK PSO-1, PSO-2, AND LTE TRIAL3*

Adverse events of special interest: POETYK PSO-1, PSO-2, and LTE Trial Part 1
Adverse events of special interest: POETYK PSO-1, PSO-2, and LTE Trial Part 1

*Includes 2 patients in SOTYKTU arm that were excluded from primary and secondary endpoint analyses.1

§MACE is defined as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.3

||VTE is defined as pulmonary embolism and deep vein thrombosis.3

AE=adverse event; COVID-19=coronavirus disease 2019; EAIR=exposure-adjusted incidence rate; LTE=long-term extension; NMSC=nonmelanoma skin cancer; PY=patient-years.

  • There were 2 deaths in the SOTYKTU arm through 1 year. An additional 8 deaths were reported in the LTE up to the cutoff date3
  • Six of these deaths were attributed to COVID-19, 1 was attributed to a ruptured thoracic aortic aneurysm (not deemed to be drug-related), and 1 was attributed to an unknown cause
  • Enrollment for LTE trial began in August 2019
  • †This represents the pooled patient population of POETYK PSO-1 and POETYK PSO-2 (Weeks 0–52). Not all patients were receiving SOTYKTU continuously throughout that period
  • ‡Two-year rates represent the pooled POETYK PSO-1 and PSO-2 populations and patients enrolled in the LTE through the 120-day cutoff date of October 1, 2021. The LTE safety analysis includes patients from POETYK PSO-1 and PSO-2 who were blindly switched from SOTYKTU, apremilast, or placebo to open-label SOTYKTU. All patients in the parent trials were eligible to enter the LTE after 52 weeks, regardless of initial treatment. 1141 patients were exposed to SOTYKTU for at least a year. Only 38.4% of patients received continuous SOTYKTU for 2 years3

SELECT IMPORTANT SAFETY INFORMATION

Infections: SOTYKTU may increase the risk of infections. Serious infections have been reported in patients with psoriasis who received SOTYKTU. The most common serious infections reported with SOTYKTU included pneumonia and COVID-19. Avoid use of SOTYKTU in patients with an active or serious infection. Consider the risks and benefits of treatment prior to initiating SOTYKTU in patients:

  • with chronic or recurrent infection
  • who have been exposed to tuberculosis
  • with a history of a serious or an opportunistic infection
  • with underlying conditions that may predispose them to infection.

Closely monitor patients for the development of signs and symptoms of infection during and after treatment. A patient who develops a new infection during treatment should undergo prompt and complete diagnostic testing, have appropriate antimicrobial therapy initiated and be closely monitored. Interrupt SOTYKTU if a patient develops a serious infection. Do not resume SOTYKTU until the infection resolves or is adequately treated.

Viral Reactivation

Herpes virus reactivation (e.g., herpes zoster, herpes simplex) was reported in clinical trials with SOTYKTU. Through Week 16, herpes simplex infections were reported in 17 patients (6.8 per 100 patient-years) treated with SOTYKTU, and 1 patient (0.8 per 100 patient-years) treated with placebo. Multidermatomal herpes zoster was reported in an immunocompetent patient. During PSO-1, PSO-2, and the open-label extension trial, the majority of patients who reported events of herpes zoster while receiving SOTYKTU were under 50 years of age. The impact of SOTYKTU on chronic viral hepatitis reactivation is unknown. Consider viral hepatitis screening and monitoring for reactivation in accordance with clinical guidelines before starting and during therapy with SOTYKTU. If signs of reactivation occur, consult a hepatitis specialist. SOTYKTU is not recommended for use in patients with active hepatitis B or hepatitis C.

PLEASE SEE ADDITIONAL IMPORTANT SAFETY INFORMATION BELOW.

See efficacy
See moa

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

SOTYKTU is contraindicated in patients with a history of hypersensitivity reaction to deucravacitinib or to any of the excipients in SOTYKTU.

WARNINGS AND PRECAUTIONS

Hypersensitivity: Hypersensitivity reactions such as angioedema have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue SOTYKTU.

Infections: SOTYKTU may increase the risk of infections. Serious infections have been reported in patients with psoriasis who received SOTYKTU. The most common serious infections reported with SOTYKTU included pneumonia and COVID-19. Avoid use of SOTYKTU in patients with an active or serious infection. Consider the risks and benefits of treatment prior to initiating SOTYKTU in patients:

  • with chronic or recurrent infection
  • who have been exposed to tuberculosis
  • with a history of a serious or an opportunistic infection
  • with underlying conditions that may predispose them to infection.

Closely monitor patients for the development of signs and symptoms of infection during and after treatment. A patient who develops a new infection during treatment should undergo prompt and complete diagnostic testing, have appropriate antimicrobial therapy initiated and be closely monitored. Interrupt SOTYKTU if a patient develops a serious infection. Do not resume SOTYKTU until the infection resolves or is adequately treated.

Viral Reactivation

Herpes virus reactivation (e.g., herpes zoster, herpes simplex) was reported in clinical trials with SOTYKTU. Through Week 16, herpes simplex infections were reported in 17 patients (6.8 per 100 patient-years) treated with SOTYKTU, and 1 patient (0.8 per 100 patient-years) treated with placebo. Multidermatomal herpes zoster was reported in an immunocompetent patient. During PSO-1, PSO-2, and the open-label extension trial, the majority of patients who reported events of herpes zoster while receiving SOTYKTU were under 50 years of age. The impact of SOTYKTU on chronic viral hepatitis reactivation is unknown. Consider viral hepatitis screening and monitoring for reactivation in accordance with clinical guidelines before starting and during therapy with SOTYKTU. If signs of reactivation occur, consult a hepatitis specialist. SOTYKTU is not recommended for use in patients with active hepatitis B or hepatitis C.

Tuberculosis (TB): In clinical trials, of 4 patients with latent TB who were treated with SOTYKTU and received appropriate TB prophylaxis, no patients developed active TB (during the mean follow-up of 34 weeks). One patient, who did not have latent TB, developed active TB after receiving 54 weeks of SOTYKTU. Evaluate patients for latent and active TB infection prior to initiating treatment with SOTYKTU. Do not administer SOTYKTU to patients with active TB. Initiate treatment of latent TB prior to administering SOTYKTU. Consider anti-TB therapy prior to initiation of SOTYKTU in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during treatment.

Malignancy including Lymphomas: Malignancies, including lymphomas, were observed in clinical trials with SOTYKTU. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with SOTYKTU, particularly in patients with a known malignancy (other than a successfully treated non-melanoma skin cancer) and patients who develop a malignancy when on treatment with SOTYKTU.

Rhabdomyolysis and Elevated CPK: Treatment with SOTYKTU was associated with an increased incidence of asymptomatic creatine phosphokinase (CPK) elevation and rhabdomyolysis compared to placebo. Discontinue SOTYKTU if markedly elevated CPK levels occur or myopathy is diagnosed or suspected. Instruct patients to promptly report unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.

Laboratory Abnormalities: Treatment with SOTYKTU was associated with increases in triglyceride levels. Periodically evaluate serum triglycerides according to clinical guidelines during treatment. SOTYKTU treatment was associated with an increase in the incidence of liver enzyme elevation compared to placebo. Evaluate liver enzymes at baseline and thereafter in patients with known or suspected liver disease according to routine management. If treatment-related increases in liver enzymes occur and drug-induced liver injury is suspected, interrupt SOTYKTU until a diagnosis of liver injury is excluded.

Immunizations: Prior to initiating therapy with SOTYKTU, consider completion of all age-appropriate immunizations according to current immunization guidelines including prophylactic herpes zoster vaccination. Avoid use of live vaccines in patients treated with SOTYKTU. The response to live or non-live vaccines has not been evaluated.

Potential Risks Related to JAK Inhibition: It is not known whether tyrosine kinase 2 (TYK2) inhibition may be associated with the observed or potential adverse reactions of Janus Kinase (JAK) inhibition. In a large, randomized, postmarketing safety trial of a JAK inhibitor in rheumatoid arthritis (RA), patients 50 years of age and older with at least one cardiovascular risk factor, higher rates of all-cause mortality, including sudden cardiovascular death, major adverse cardiovascular events, overall thrombosis, deep venous thrombosis, pulmonary embolism, and malignancies (excluding non-melanoma skin cancer) were observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. SOTYKTU is not approved for use in RA.

ADVERSE REACTIONS

Most common adverse reactions (≥1% of patients on SOTYKTU and more frequently than with placebo) include upper respiratory infections, blood creatine phosphokinase increased, herpes simplex, mouth ulcers, folliculitis and acne.

SPECIFIC POPULATIONS

Pregnancy: Available data from case reports on SOTYKTU use during pregnancy are insufficient to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Report pregnancies to the Bristol-Myers Squibb Company’s Adverse Event reporting line at 1-800-721-5072.

Lactation: There are no data on the presence of SOTYKTU in human milk, the effects on the breastfed infant, or the effects on milk production. SOTYKTU is present in rat milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for SOTYKTU and any potential adverse effects on the breastfed infant from SOTYKTU or from the underlying maternal condition.

Hepatic Impairment: SOTYKTU is not recommended for use in patients with severe hepatic impairment.

SOTYKTU is available in 6 mg tablets.

INDICATION

SOTYKTU™ (deucravacitinib) is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Limitations of Use:

SOTYKTU is not recommended for use in combination with other potent immunosuppressants.

Please see U.S. Full Prescribing Information, including Medication Guide, for SOTYKTU.

References:

1. SOTYKTU [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2022.

2. Chimalakonda A, Burke J, Cheng L, et al. Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with Janus kinase 1/2/3 inhibitors. Dermatol Ther (Heidelb). 2021:11(5);1763-1776.

References:

1. SOTYKTU [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2022.

2. Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial [published online ahead of print, 2022 Jul 9]. J Am Acad Dermatol. 2022; https://doi.org/10.1016/j.jaad.2022.07.002.

3. Strober B, Thaçi D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial. J Am Acad Dermatol. 2022;S0190-9622(22)02643-3. doi: 10.1016/j.jaad.2022.08.061

4. Warren RB, Sofen H, Imafuku S, et al. Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program. Presented at: European Academy of Dermatology and Venereology (EADV) Spring Symposium; May 12-May 14, 2022; Ljubljana, Slovenia.

5. Warren RB, Armstrong A, Imafuku S, et al. Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy analysis by prior treatment in the phase 3 POETYK PSO-1 and POETYK PSO-2 trials. Oral presentation at: European Academy of Dermatology and Venereology (EADV) 30th Congress; September 29-October 2, 2021; Virtual Meeting.

6. Gooderman M, Kircik L, Spelman L, et al. Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy by prespecified baseline demographics in the phase 3 POETYK PSO-1 and POETYK PSO-2 trials. Presented at: European Academy of Dermatology and Venereology (EADV) 30th Congress; September 29-October 2, 2021; Virtual Meeting.

References:

1. SOTYKTU [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2022.

2. Data on file. BMS-REF-DEU-0020. Princeton, NJ: Bristol-Myers Squibb Company; 2022.

3. Strober B, Thaçi D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial. J Am Acad Dermatol. 2022;S0190-9622(22)02643-3. doi: 10.1016/j.jaad.2022.08.061

4. Data on file. BMS-REF-DEU-0021. Princeton, NJ: Bristol-Myers Squibb Company; 2022.

5. Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial [published online ahead of print, 2022 Jul 9]. J Am Acad Dermatol. 2022; https://doi.org/10.1016/j.jaad.2022.07.002.

References:

1. SOTYKTU [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2022.

2. Armstrong A, Gooderham M, Warren RB, et al. Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor compared with placebo and apremilast in moderate to severe plaque psoriasis: results from the POETYK PSO-1 study. Oral presentation at: American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX); April 23-25, 2021; Virtual Meeting.

3. Warren RB, Sofen H, lmafuku S, et al. Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program. Presented at: European Academy of Dermatology and Venereology (EADV) Spring Symposium; May 12-May 14, 2022; Ljubljana, Slovenia.

References:

1. SOTYKTU [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2022.

2. Chimalakonda A, Burke J, Cheng L, et al. Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with Janus kinase 1/2/3 inhibitors. Dermatol Ther (Heidelb). 2021;11(5):1763-1776.

3. Di Cesare A, Di Meglio P. Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129(6):1339-1350.

Reference:

1. SOTYKTU [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2022.

SOTYKTU, SOTYKTU 360 SUPPORT, and SOTYKTU
logo
are trademarks of Bristol-Myers Squibb Company.

© 2023 Bristol-Myers Squibb Company.

Otezla is a registered trademark of Amgen Inc

1787-US-2200576 09/22

1787-US-2200110 09/22

Legal Notice|Privacy Policy|Sitemap
Bristol Myers Squibb™ Logo

SOTYKTU, SOTYKTU 360 SUPPORT, and SOTYKTU
logo
are trademarks of Bristol-Myers Squibb Company.

© 2023 Bristol-Myers Squibb Company.

Otezla is a registered trademark of Amgen Inc

1787-US-2200720 12/22

1787-US-2200110 09/22

Legal Notice|Privacy Policy|Sitemap
Bristol Myers Squibb™ Logo

SOTYKTU, SOTYKTU 360 SUPPORT, and SOTYKTU
logo
are trademarks of Bristol-Myers Squibb Company.

© 2023 Bristol-Myers Squibb Company.

Otezla is a registered trademark of Amgen Inc

1787-US-2200720 12/22

1787-US-2200110 09/22

Legal Notice|Privacy Policy|Sitemap